Sigcap Pharmaceuticals (I) Private Limited
About Sigcap Pharmaceuticals (I) Private Limited
Data last updated:
Sigcap Pharmaceuticals (I) Private Limited was a private limited company based in Kolkata, West Bengal, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 October 2007.
The company was registered with the Registrar of Companies (ROC), Kolkata, under CIN U24232WB2007PTC120042.
The company had an authorised share capital of ₹1 Cr and a paid-up capital of ₹78.75 Lakh. It was led by directors Rahul Todi and Seema Jain.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office was at 686 Anandapur 7th Floor E.M. Bypass R.B. Connector Junction, Kolkata, West Bengal, India – 700107.
Company details
Contact details
Sigcap Pharmaceuticals (I) Private Limited's registered office is in Kolkata, West Bengal. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address686 Anandapur 7th Floor E.M. Bypass R.B. Connector Junction, Kolkata, West Bengal, India – 700107
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Sigcap Pharmaceuticals (I) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Sigcap Pharmaceuticals (I) Private Limited
FY 2023 filings availableSigcap Pharmaceuticals (I) Private Limited reported revenue of ₹1,326 (up 14% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue rose 14% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 33%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Sigcap Pharmaceuticals (I) Private Limited, buy the company report.
Board of directors of Sigcap Pharmaceuticals (I) Private Limited
Sigcap Pharmaceuticals (I) has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rahul Todi Also directs: Red Cherry Hospitality LLP, Calcutta Becon Engineering Co LLP, SJB Estates LLP and 5 more | Director | 25 Oct 2007 | 19 Years 0 Months | As last reported |
| Seema Jain | Director | 30 Aug 2022 | 4 Years 2 Months | As last reported |
Peer comparison
Sigcap Pharmaceuticals (I) Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| A4 Pharma Private Limited | ₹1,567 (FY 2025) | -99.0% | Faridabad, Haryana, India | |||
| Karjee Pharmaceuticals Private Limited | ₹1,500 (FY 2024) | -99.0% | Lucknow, Uttar Pradesh, India | |||
| Aqua-Cap Software Consultancy Services Private Limited | ₹1,498 (FY 2024) | 149.0% | Bangalore, Karnataka, India | |||
| Indian Pharmaceutical Research Laboratories Private Limited | ₹1,440 (FY 2025) | 1100.0% | Mumbai, Maharashtra, India | |||
| Kypros Pharmaceuticals Private Limited | ₹1,426 (FY 2025) | -39.0% | Pune, Maharashtra, India | |||
| Sigcap Pharmaceuticals (I) Private Limitedthis company | ₹1,326 (FY 2023) | 14.0% | Kolkata, West Bengal, India | |||
| Empathy Lifesciences Private Limited | ₹1,237 (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| R R Biotec India Private Limited | ₹1,218 (FY 2024) | -93.0% | Kala Amb, Himachal Pradesh, India | |||
| Emson Medi Chem Private Limited | ₹1,218 (FY 2021) | 46.0% | Mumbai, Maharashtra, India | |||
| P and V Formulations Private Limited | ₹1,200 (FY 2025) | Rajura, Maharashtra, India | ||||
| Ardheesh Chemicals Pvt Ltd | ₹1,130 (FY 2024) | -84.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Sigcap Pharmaceuticals (I) Private Limited, buy the company report.
Auditor
Sigcap Pharmaceuticals (I) Private Limited is audited by JAIN SARAWGEE & CO for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| JAIN SARAWGEE & CO | FY 2019 | 306087E |
Shareholding
The shareholding of Sigcap Pharmaceuticals (I) Private Limited is on record for 3 financial years, the latest being FY 2019, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Sigcap Pharmaceuticals (I) Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Sigcap Pharmaceuticals (I) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Sigcap Pharmaceuticals (I) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Sigcap Pharmaceuticals (I) Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Sigcap Pharmaceuticals (I) Private Limited has 8 board changes on record since 2007: 2 appointments and 6 cessations. The latest: Seema Jain ceased to be Additional Director on 30 Sep 2022.
Frequently asked questions
Sigcap Pharmaceuticals (I) has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Sigcap Pharmaceuticals (I) was a private limited company based in Kolkata, West Bengal, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 25 October 2007 and is registered under CIN U24232WB2007PTC120042. The company has been struck off by the Registrar of Companies and is no longer operational.
Sigcap Pharmaceuticals (I) had 2 directors:
- Rahul Todi - Director
- Seema Jain - Director
The CIN (Corporate Identification Number) of Sigcap Pharmaceuticals (I) is U24232WB2007PTC120042. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Sigcap Pharmaceuticals (I) is at 686 Anandapur 7th Floor E.M. Bypass R.B. Connector Junction, Kolkata, West Bengal, India – 700107.
Sigcap Pharmaceuticals (I) was incorporated on 25 October 2007. It is registered with the Registrar of Companies, Kolkata.
The latest financial statements of Sigcap Pharmaceuticals (I) on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 30 September 2023. Year-wise statements from 2015 are in the company report.
Sigcap Pharmaceuticals (I) operated in the pharma industry, in the drug formulation and development segment. It worked in this industry before it was struck off.
The peers of Sigcap Pharmaceuticals (I) by revenue are A4 Pharma Private Limited, Karjee Pharmaceuticals Private Limited, Aqua-Cap Software Consultancy Services Private Limited, Indian Pharmaceutical Research Laboratories Private Limited, Kypros Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Seema Jain ceased to be Additional Director on 30 Sep 2022. Anshuman Sarkar ceased to be Director on 30 Aug 2022. Seema Jain was appointed as Director on 30 Aug 2022. Sigcap Pharmaceuticals (I) has 8 board changes on record in total.
The compliance status of Sigcap Pharmaceuticals (I) is compliant as of 13 August 2026.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
